波士顿科学公司一位高管近日表示，尽管中国市场竞争激烈、运营环境复杂，但公司对该市场的长期增长潜力仍持积极态度。
这位高管指出，虽然中国市场准入和监管要求严格，但庞大的患者群体和不断升级的医疗需求为医疗器械行业提供了持续机遇。公司将继续通过本土化创新和深化合作来应对挑战，并看好中国在数字医疗和微创手术领域的发展前景。
值得注意的是，随着中国医疗改革深入推进，高端医疗器械进口替代进程加速，跨国企业需要更灵活地调整战略。波士顿科学正通过加强本土研发和扩大生产线来适应这一趋势，其最新推出的血管介入产品已获得中国监管机构批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.